Ranolazine Side Effects and Precautions
Introduction to Ranolazine Side Effects
- The American Heart Association recommends that patients should be informed about common side effects of ranolazine, such as constipation, nausea, dizziness, and headache, and monitored for QT prolongation, particularly when taking other medications that affect the QT interval or in those with hepatic or renal impairment 1, 2, 3
Common Side Effects
- Constipation is a common side effect of ranolazine, with a dose-dependent QT interval prolongation that requires monitoring, especially in patients with risk factors for arrhythmias 1, 3
- Nausea is a common side effect of ranolazine, with a dose-dependent QT interval prolongation that requires monitoring, especially in patients with risk factors for arrhythmias 1, 3
- Dizziness is a common side effect of ranolazine, with a dose-dependent QT interval prolongation that requires monitoring, especially in patients with risk factors for arrhythmias 1, 3
- Headache is a common side effect of ranolazine, with a dose-dependent QT interval prolongation that requires monitoring, especially in patients with risk factors for arrhythmias 1, 3
Cardiovascular Effects
- QT interval prolongation is a dose-dependent side effect of ranolazine, which may increase the risk of torsades de pointes, especially in patients with risk factors for arrhythmias 1, 3, 5
- Ranolazine has minimal effects on heart rate and blood pressure, but may increase the risk of QT prolongation when combined with other QT-prolonging drugs 1, 3, 5
Special Populations and Risk Factors
Hepatic Impairment
- The American College of Cardiology recommends that ranolazine is contraindicated in patients with hepatic impairment or liver cirrhosis, due to the risk of drug accumulation and severe adverse effects 4, 5, 7
Renal Impairment
- The National Kidney Foundation recommends that the dose of ranolazine should be limited to 500 mg twice daily in patients with severe renal impairment (CrCl <30 ml/min), due to the increased risk of adverse effects 6
Drug Interactions
P-glycoprotein Substrates
- The European Society of Cardiology recommends that ranolazine should be used with caution in patients taking digoxin, as it may increase digoxin concentration by 40-60% through P-glycoprotein inhibition 4, 7
Monitoring Recommendations
- The American Heart Association recommends ECG monitoring for QT prolongation in high-risk patients taking ranolazine, especially when combined with other QT-prolonging drugs 5
- The American College of Cardiology recommends monitoring digoxin levels when co-administered with ranolazine, due to the increased risk of adverse effects 4, 7